Tumor B7-H3 expression in diagnostic biopsy specimens and survival in patients with metastatic prostate cancer.
Journal
Prostate cancer and prostatic diseases
ISSN: 1476-5608
Titre abrégé: Prostate Cancer Prostatic Dis
Pays: England
ID NLM: 9815755
Informations de publication
Date de publication:
09 2021
09 2021
Historique:
received:
15
09
2020
accepted:
20
01
2021
revised:
06
01
2021
pubmed:
10
2
2021
medline:
2
2
2022
entrez:
9
2
2021
Statut:
ppublish
Résumé
Prostate cancer spans a broad spectrum from indolent to deadly disease. In the management of prostate cancer, diagnostic biopsy specimens are important sources of data that inform the selection of treatment. B7-H3 (CD276), an immune checkpoint molecule, has emerged as a promising immunotherapy target. B7-H3 expression is related to adverse clinical outcomes in various types of cancer; however, little is known concerning the association between tumor B7-H3 expression in diagnostic biopsy specimens and clinical outcome in patients with metastatic prostate cancer. We evaluated tumor B7-H3 expression levels in diagnostic biopsy specimens from 135 patients with metastatic prostate cancer and 113 patients with localized prostate cancer. High B7-H3 expression was more frequently observed in patients with metastatic cancer than in those with localized cancer (31 vs. 12%; p = 0.0003). In patients with localized cancer, the B7-H3 expression status was not associated with biochemical recurrence-free survival. However, among patients with metastatic cancer, high B7-H3 expression was independently associated with high disease-specific mortality (multivariable hazard ratio [HR] = 2.72; p = 0.047) and overall mortality rates (multivariable HR = 2.04; p = 0.025). Tumor B7-H3 expression in diagnostic biopsy specimens may be a useful biomarker for identifying highly aggressive metastatic prostate cancer. Given the potential utility of anti-B7-H3 immunotherapy, this information may aid in stratifying prostate cancer based on its responsiveness to B7-H3-targeted treatment.
Sections du résumé
BACKGROUND
Prostate cancer spans a broad spectrum from indolent to deadly disease. In the management of prostate cancer, diagnostic biopsy specimens are important sources of data that inform the selection of treatment. B7-H3 (CD276), an immune checkpoint molecule, has emerged as a promising immunotherapy target. B7-H3 expression is related to adverse clinical outcomes in various types of cancer; however, little is known concerning the association between tumor B7-H3 expression in diagnostic biopsy specimens and clinical outcome in patients with metastatic prostate cancer.
METHODS
We evaluated tumor B7-H3 expression levels in diagnostic biopsy specimens from 135 patients with metastatic prostate cancer and 113 patients with localized prostate cancer.
RESULTS
High B7-H3 expression was more frequently observed in patients with metastatic cancer than in those with localized cancer (31 vs. 12%; p = 0.0003). In patients with localized cancer, the B7-H3 expression status was not associated with biochemical recurrence-free survival. However, among patients with metastatic cancer, high B7-H3 expression was independently associated with high disease-specific mortality (multivariable hazard ratio [HR] = 2.72; p = 0.047) and overall mortality rates (multivariable HR = 2.04; p = 0.025).
CONCLUSIONS
Tumor B7-H3 expression in diagnostic biopsy specimens may be a useful biomarker for identifying highly aggressive metastatic prostate cancer. Given the potential utility of anti-B7-H3 immunotherapy, this information may aid in stratifying prostate cancer based on its responsiveness to B7-H3-targeted treatment.
Identifiants
pubmed: 33558663
doi: 10.1038/s41391-021-00331-6
pii: 10.1038/s41391-021-00331-6
doi:
Substances chimiques
B7 Antigens
0
Biomarkers, Tumor
0
CD276 protein, human
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
767-774Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer Nature Limited part of Springer Nature.
Références
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70:7–30.
doi: 10.3322/caac.21590
pubmed: 31912902
Sathianathen NJ, Konety BR, Crook J, Saad F, Lawrentschuk N. Landmarks in prostate cancer. Nat Rev Urol. 2018;15:627–42.
pubmed: 30065357
doi: 10.1038/s41585-018-0060-7
Hoogland AM, Kweldam CF, van Leenders GJ. Prognostic histopathological and molecular markers on prostate cancer needle-biopsies: a review. Biomed Res Int. 2014;2014:341324.
pubmed: 25243131
pmcid: 4163394
doi: 10.1155/2014/341324
Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359:1350–5.
pubmed: 29567705
pmcid: 7391259
doi: 10.1126/science.aar4060
Boettcher AN, Usman A, Morgans A, VanderWeele DJ, Sosman J, Wu JD. Past current, and future of immunotherapies for prostate cancer. Front Oncol. 2019;9:884.
pubmed: 31572678
pmcid: 6749031
doi: 10.3389/fonc.2019.00884
Miller AM, Pisa P. Tumor escape mechanisms in prostate cancer. Cancer Immunol Immunother. 2007;56:81–7.
pubmed: 16362411
doi: 10.1007/s00262-005-0110-x
Comiskey MC, Dallos MC, Drake CG. Immunotherapy in prostate cancer: teaching an old dog new tricks. Curr Oncol Rep. 2018;20:75.
pubmed: 30120592
doi: 10.1007/s11912-018-0712-z
Seaman S, Zhu Z, Saha S, Zhang XM, Yang MY, Hilton MB, et al. Eradication of tumors through simultaneous ablation of CD276/B7-H3-positive tumor cells and tumor vasculature. Cancer Cell. 2017;31:501–15 e8.
pubmed: 28399408
pmcid: 5458750
doi: 10.1016/j.ccell.2017.03.005
Du H, Hirabayashi K, Ahn S, Kren NP, Montgomery SA, Wang X, et al. Antitumor responses in the absence of toxicity in solid tumors by targeting B7-H3 via chimeric antigen receptor t cells. Cancer Cell. 2019;35:221–37.e8.
pubmed: 30753824
pmcid: 6645919
doi: 10.1016/j.ccell.2019.01.002
Flem-Karlsen K, Fodstad Y, Nunes-Xavier CE. B7-H3 immune checkpoint protein in human cancer. Curr Med Chem. 2019;19:180–5.
doi: 10.2174/1568026619666190308131805
Flem-Karlsen K, Fodstad Ø, Tan M, Nunes-Xavier CE. B7-H3 in cancer—beyond immune regulation. Trends Cancer. 2018;4:401–4.
pubmed: 29860983
doi: 10.1016/j.trecan.2018.03.010
Castellanos JR, Purvis IJ, Labak CM, Guda MR, Tsung AJ, Velpula KK, et al. B7-H3 role in the immune landscape of cancer. Am J Clin Exp Immunol. 2017;6:66–75.
pubmed: 28695059
pmcid: 5498853
Roth TJ, Sheinin Y, Lohse CM, Kuntz SM, Frigola X, Inman BA, et al. B7-H3 ligand expression by prostate cancer: a novel marker of prognosis and potential target for therapy. Cancer Res. 2007;67:7893–900.
pubmed: 17686830
doi: 10.1158/0008-5472.CAN-07-1068
Benzon B, Zhao SG, Haffner MC, Takhar M, Erho N, Yousefi K, et al. Correlation of B7-H3 with androgen receptor, immune pathways and poor outcome in prostate cancer: an expression-based analysis. Prostate Cancer Prostatic Dis. 2017;20:28–35.
pubmed: 27801901
doi: 10.1038/pcan.2016.49
Liu Y, Vlatkovic L, Saeter T, Servoll E, Waaler G, Nesland JM, et al. Is the clinical malignant phenotype of prostate cancer a result of a highly proliferative immune-evasive B7-H3-expressing cell population? Int J Urol. 2012;19:749–56.
pubmed: 22487487
doi: 10.1111/j.1442-2042.2012.03017.x
Zang X, Thompson RH, Al-Ahmadie HA, Serio AM, Reuter VE, Eastham JA, et al. B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome. Proc Natl Acad Sci USA. 2007;104:19458–63.
pubmed: 18042703
pmcid: 2148311
doi: 10.1073/pnas.0709802104
Inamura K, Takazawa Y, Inoue Y, Yokouchi Y, Kobayashi M, Saiura A, et al. Tumor B7-H3 (CD276) expression and survival in pancreatic cancer. J Clin Med. 2018;7:172.
pmcid: 6069252
doi: 10.3390/jcm7070172
Inamura K, Yokouchi Y, Kobayashi M, Sakakibara R, Ninomiya H, Subat S, et al. Tumor B7-H3 (CD276) expression and smoking history in relation to lung adenocarcinoma prognosis. Lung Cancer. 2017;103:44–51.
pubmed: 28024695
doi: 10.1016/j.lungcan.2016.11.013
Inamura K, Amori G, Yuasa T, Yamamoto S, Yonese J, Ishikawa Y. Relationship of B7-H3 expression in tumor cells and tumor vasculature with FOXP3+ regulatory T cells in renal cell carcinoma. Cancer Manag Res. 2019;11:7021–30.
pubmed: 31440091
pmcid: 6664858
doi: 10.2147/CMAR.S209205
Sanda MG, Restifo NP, Walsh JC, Kawakami Y, Nelson WG, Pardoll DM, et al. Molecular characterization of defective antigen processing in human prostate cancer. J Natl Cancer Inst. 1995;87:280–5.
pubmed: 7707419
doi: 10.1093/jnci/87.4.280
Abusamra AJ, Zhong Z, Zheng X, Li M, Ichim TE, Chin JL, et al. Tumor exosomes expressing Fas ligand mediate CD8+ T-cell apoptosis. Blood Cells Mol Dis. 2005;35:169–73.
pubmed: 16081306
doi: 10.1016/j.bcmd.2005.07.001
Shafer-Weaver KA, Anderson MJ, Stagliano K, Malyguine A, Greenberg NM, Hurwitz AA. Cutting edge: tumor-specific CD8+ T cells infiltrating prostatic tumors are induced to become suppressor cells. J Immunol. 2009;183:4848–52.
pubmed: 19801511
doi: 10.4049/jimmunol.0900848
Pasero C, Gravis G, Guerin M, Granjeaud S, Thomassin-Piana J, Rocchi P, et al. Inherent and tumor-driven immune tolerance in the prostate microenvironment impairs natural killer cell antitumor activity. Cancer Res. 2016;76:2153–65.
pubmed: 27197252
doi: 10.1158/0008-5472.CAN-15-1965
Miller AM, Lundberg K, Ozenci V, Banham AH, Hellstrom M, Egevad L, et al. CD4+CD25 high T cells are enriched in the tumor and peripheral blood of prostate cancer patients. J Immunol. 2006;177:7398–405.
pubmed: 17082659
doi: 10.4049/jimmunol.177.10.7398
Sfanos KS, Bruno TC, Maris CH, Xu L, Thoburn CJ, DeMarzo AM, et al. Phenotypic analysis of prostate-infiltrating lymphocytes reveals TH17 and Treg skewing. Clin Cancer Res. 2008;14:3254–61.
pubmed: 18519750
pmcid: 3082357
doi: 10.1158/1078-0432.CCR-07-5164
Chapoval AI, Ni J, Lau JS, Wilcox RA, Flies DB, Liu D, et al. B7-H3: a costimulatory molecule for T cell activation and IFN-gamma production. Nat Immunol. 2001;2:269–74.
pubmed: 11224528
doi: 10.1038/85339
Ceeraz S, Nowak EC, Noelle RJ. B7 family checkpoint regulators in immune regulation and disease. Trends Immunol. 2013;34:556–63.
pubmed: 23954143
doi: 10.1016/j.it.2013.07.003
Kontos F, Michelakos T, Kurokawa T, Sadagopan A, Schwab JH, Ferrone CR, et al. B7-H3: an attractive target for antibody-based immunotherapy. Clin Cancer Res. 2020. https://doi.org/10.1158/1078-0432.CCR-20-2584 .
Prasad DV, Nguyen T, Li Z, Yang Y, Duong J, Wang Y, et al. Murine B7-H3 is a negative regulator of T cells. J Immunol. 2004;173:2500–6.
pubmed: 15294965
doi: 10.4049/jimmunol.173.4.2500
Suh WK, Gajewska BU, Okada H, Gronski MA, Bertram EM, Dawicki W, et al. The B7 family member B7-H3 preferentially down-regulates T helper type 1-mediated immune responses. Nat Immunol. 2003;4:899–906.
pubmed: 12925852
doi: 10.1038/ni967
Picarda E, Ohaegbulam KC, Zang X. Molecular pathways: targeting B7-H3 (CD276) for human cancer immunotherapy. Clin Cancer Res. 2016;22:3425–31.
pubmed: 27208063
pmcid: 4947428
doi: 10.1158/1078-0432.CCR-15-2428
Suh WK, Wang SX, Jheon AH, Moreno L, Yoshinaga SK, Ganss B, et al. The immune regulatory protein B7-H3 promotes osteoblast differentiation and bone mineralization. Proc Natl Acad Sci USA. 2004;101:12969–73.
pubmed: 15317945
pmcid: 516502
doi: 10.1073/pnas.0405259101
Lu Z, Zhao ZX, Cheng P, Huang F, Guan X, Zhang MG, et al. B7-H3 immune checkpoint expression is a poor prognostic factor in colorectal carcinoma. Mod Pathol. 2020;33:2330–40.
pubmed: 32514163
doi: 10.1038/s41379-020-0587-z
Yim J, Koh J, Kim S, Song SG, Ahn HK, Kim YA, et al. Effects of B7-H3 expression on tumour-infiltrating immune cells and clinicopathological characteristics in non-small-cell lung cancer. Eur J Cancer. 2020;133:74–85.
pubmed: 32447027
doi: 10.1016/j.ejca.2020.03.033
Lee YH, Martin-Orozco N, Zheng P, Li J, Zhang P, Tan H, et al. Inhibition of the B7-H3 immune checkpoint limits tumor growth by enhancing cytotoxic lymphocyte function. Cell Res. 2017;27:1034–45.
pubmed: 28685773
pmcid: 5539354
doi: 10.1038/cr.2017.90
Liu H, Tekle C, Chen YW, Kristian A, Zhao Y, Zhou M, et al. B7-H3 silencing increases paclitaxel sensitivity by abrogating Jak2/Stat3 phosphorylation. Mol Cancer Ther. 2011;10:960–71.
pubmed: 21518725
pmcid: 3253760
doi: 10.1158/1535-7163.MCT-11-0072
Nunes-Xavier CE, Karlsen KF, Tekle C, Pedersen C, Øyjord T, Hongisto V, et al. Decreased expression of B7-H3 reduces the glycolytic capacity and sensitizes breast cancer cells to AKT/mTOR inhibitors. Oncotarget. 2016;7:6891–901.
pubmed: 26771843
pmcid: 4872756
doi: 10.18632/oncotarget.6902
Tekle C, Nygren MK, Chen YW, Dybsjord I, Nesland JM, Maelandsmo GM, et al. B7-H3 contributes to the metastatic capacity of melanoma cells by modulation of known metastasis-associated genes. Int J Cancer. 2012;130:2282–90.
pubmed: 21671471
doi: 10.1002/ijc.26238
Zupancic M, Pospihalj B, Cerovic S, Gazic B, Drev P, Hocevar M, et al. Significance of nuclear factor—kappa beta activation on prostate needle biopsy samples in the evaluation of Gleason score 6 prostatic carcinoma indolence. Radio Oncol. 2020;54:194–200.
doi: 10.2478/raon-2020-0019
Zinger A, Cho WC, Ben-Yehuda A. Cancer and aging—the inflammatory connection. Aging Dis. 2017;8:611–27.
pubmed: 28966805
pmcid: 5614325
doi: 10.14336/AD.2016.1230
Yuan H, Wei X, Zhang G, Li C, Zhang X, Hou J. B7-H3 over expression in prostate cancer promotes tumor cell progression. J Urol. 2011;186:1093–9.
pubmed: 21784485
doi: 10.1016/j.juro.2011.04.103
Kreymborg K, Haak S, Murali R, Wei J, Waitz R, Gasteiger G, et al. Ablation of B7-H3 but not B7-H4 results in highly increased tumor burden in a murine model of spontaneous prostate cancer. Cancer Immunol Res. 2015;3:849–54.
pubmed: 26122284
pmcid: 5939565
doi: 10.1158/2326-6066.CIR-15-0100